Veterans with COPD and current tobacco use faced a reduced likelihood for tobacco dependence treatment if they lived in a ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in ...

Cytisinicline significantly increases quit rates in smokers with or without COPD while being safe and well tolerated.

The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

Professor of Respiratory Medicine and Allergy at the National Heart and Lung Institute, Imperial College London -- presented positive findings demonstrating the beneficial effects of Altesa ...

US FDA assent for 4D Medical’s CT VQ ventilation perfusion device described by the company as a “transformational milestone”.

Researchers may have found a safe and effective treatment for chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) ...

A few months after her surgery, in March 2022, Karen’s doctor suggested immunotherapy, to ensure that the cancer didn’t ...

Chronic respiratory diseases are among the top causes of death and disability worldwide, yet receive little political or ...

The effect of chronic breathlessness on the lives of patients and their loved ones is tremendous, regardless of the ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second ...